Ratings Pfizer, Inc.

Equities

PFE

US7170811035

Market Closed - Nyse 04:00:23 2024-03-18 pm EDT 5-day change 1st Jan Change
27.72 USD -0.79% Intraday chart for Pfizer, Inc. -2.29% -3.72%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • The company is one of the best yield companies with high dividend expectations.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • One of the major weak points of the company is its financial situation.
  • The company's enterprise value to sales, at 3.37 times its current sales, is high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
-3.72% 157B
C+
+30.83% 687B
C+
+30.96% 595B
B
+0.01% 378B
C+
+15.18% 316B
C+
+11.39% 308B
B-
+0.78% 211B
B-
-6.09% 208B
A+
-2.92% 203B
B+
-5.94% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes